Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
← catalyst calendarNCT07258290 · readout ≤ 1,046 d
Sponsored by Teleflex (industry) · TFX — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
1,859estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | Jun 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Coronary Disease
- Heart Diseases
- Cardiovascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Vascular Diseases
- Chest Pain
- Pain
- Neurologic Manifestations
- Signs and Symptoms
- Pathological Conditions, Signs and Symptoms
- Coronary Artery Disease
- Myocardial Ischemia
- Acute Coronary Syndrome
- Angina Pectoris
Interventions
- Device: Freesolve RMS
- Device: Xience DES
Primary outcome
what the primary-completion date above is the date OFTarget Lesion Failure (TLF) rate at 12 months post-index procedure
measured 12 months
Permalink · TFX's whole pipeline · Catalyst calendar · Every registered study · What changed